Notice of results
03 May 2022
Analyst & investor
presentations
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on
the prevention of cardiovascular disease, announces it will issue its
preliminary results for the year ended 31 December 2021 on Tuesday, 17 May
2022.
Matthew Walls, CEO, and Paul Foulger, CFO will host an in-person analyst meeting
at the offices of Walbrook PR, 75 King William Street, London EC4N 7BE at 9.30am
on 17 May. If you would like to attend, please contact Walbrook PR at genincode@walbrookpr.com
or on 020 7933 8780.
The Company will also host a presentation for investors via the IMC platform at 3pm on 17 May. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. To register for this, please use the following link: https://www.investormeetcompany.com/genincode-plc/register-investor
For more information visit www.genincode.com
GENinCode Plc | www.genincode.com or via Walbrook PR | |
---|---|---|
Matthew Walls, CEO | ||
Paul Foulger, CFO | ||
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |
Alex Price / Ben Maddison / Richard Short | ||
Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |
Giles Balleny | ||
Dale Bellis / Michael Johnson (Sales) | ||
Walbrook PR Limited | Tel: 020 7933 8780 or | |
Anna Dunphy / Paul McManus / Louis Ashe-Jepson | genincode@walbrookpr.com |
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death and
disability worldwide.
GENinCode operates business units in the UK, in the United States through
GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The
effects of behavioural risk factors may show up in individuals as raised blood
pressure, raised
blood glucose, raised blood lipids, and overweight and obesity. These
“intermediate risks factors” can be measured in primary care facilities and
indicate an increased risk of heart attack, stroke, heart failure and other
complications.
Cessation of tobacco use, reduction of salt in the diet, eating more fruit and
vegetables, regular physical activity and avoiding harmful use of alcohol have
been shown to reduce the risk of cardiovascular disease. Health policies that
create conducive
environments for making healthy choices affordable and available are essential
for motivating people to adopt and sustain healthy behaviours.
Identifying those at highest risk of CVDs and ensuring they receive appropriate
treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to
ensure that those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas and is the single biggest area where the
NHS can save lives over the next 10 years. CVD is largely preventable, through
lifestyle changes and
a combination of public health and NHS action on smoking and tobacco addiction,
obesity, tackling alcohol misuse and food reformulation.
Genetic risk assessment can help early detection and treatment of CVD to help
patients live longer, healthier lives. Many people are still living with
undetected, high-risk conditions such as high blood pressure, raised
cholesterol, and atrial fibrillation
(AF). Progress continues in the NHS to identify and diagnose people routinely
knowing their ‘ABC' (testing and monitoring of AF, Blood pressure and
Cholesterol) set out in the NHS 10 Year plan.